JP2008522597A - Ｉｉ型糖尿病に関連する単一ヌクレオチド多型（ｓｎｐ） - Google Patents

Ｉｉ型糖尿病に関連する単一ヌクレオチド多型（ｓｎｐ） Download PDF

Info

Publication number
JP2008522597A
JP2008522597A JP2007544791A JP2007544791A JP2008522597A JP 2008522597 A JP2008522597 A JP 2008522597A JP 2007544791 A JP2007544791 A JP 2007544791A JP 2007544791 A JP2007544791 A JP 2007544791A JP 2008522597 A JP2008522597 A JP 2008522597A
Authority
JP
Japan
Prior art keywords
seq
snp
complement
polynucleotide
diabetes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007544791A
Other languages
English (en)
Japanese (ja)
Inventor
マレク ファハム
セーレン ゲルマー
ハイウェル バウデン ジョーンズ
ミッチェル リー マーティン
マーティン エミリオ ムーアヘッド
エリック ロイ ラスムッセン
ジェームズ アンドリュー ロシンスキ
デルフィーヌ ラガルド
ブライアン ケント リース
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2008522597A publication Critical patent/JP2008522597A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Veterinary Medicine (AREA)
  • General Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2007544791A 2004-12-13 2005-12-05 Ｉｉ型糖尿病に関連する単一ヌクレオチド多型（ｓｎｐ） Pending JP2008522597A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63556304P 2004-12-13 2004-12-13
US71432105P 2005-09-06 2005-09-06
PCT/EP2005/012986 WO2006063703A2 (fr) 2004-12-13 2005-12-05 Polymorphisme a simple nucleotide (snp)

Publications (1)

Publication Number Publication Date
JP2008522597A true JP2008522597A (ja) 2008-07-03

Family

ID=35799724

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007544791A Pending JP2008522597A (ja) 2004-12-13 2005-12-05 Ｉｉ型糖尿病に関連する単一ヌクレオチド多型（ｓｎｐ）

Country Status (4)

Country Link
EP (1) EP1828417A2 (fr)
JP (1) JP2008522597A (fr)
CA (1) CA2589037A1 (fr)
WO (1) WO2006063703A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008087204A1 (fr) * 2007-01-19 2008-07-24 Integragen Gène btbd9 de susceptibilité au diabète humain
US20110129820A1 (en) * 2007-04-10 2011-06-02 Integragen Human diabetes susceptibility tnfrsf10b gene
US20100285459A1 (en) * 2007-04-10 2010-11-11 Integragen Corporation Human Diabetes Susceptibility TNFRSF10A gene
US20100105057A1 (en) * 2007-04-10 2010-04-29 Anne Philippi Human diabetes susceptibility tnfrsf10d gene
EP2134867A1 (fr) * 2007-04-10 2009-12-23 Integragen Gène tnfrsf10c de susceptibilité au diabète chez l'homme
CA2684661A1 (fr) * 2007-05-04 2008-11-13 Integragen Gene eefsec humain de predisposition au diabete
CN103882127B (zh) * 2014-03-13 2016-03-16 河北联合大学 用于预测患2型糖尿病肾病发生风险的试剂盒

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004084797A2 (fr) * 2003-02-28 2004-10-07 Hubit Genomix Inc Gene associe au diabete sucre du type 2 et son utilisation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5863724A (en) * 1994-04-13 1999-01-26 Baylor College Of Medicine Methods of screening for persistent hyperinsulinemic hypoglycemia of infancy
US6783942B2 (en) * 1998-10-08 2004-08-31 Uab Research Foundation Isolated polynucleotide associated with type II diabetes mellitus and methods of use thereof
WO2002052044A2 (fr) * 2000-12-27 2002-07-04 Riken Detection de polymorphismes genetiques

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004084797A2 (fr) * 2003-02-28 2004-10-07 Hubit Genomix Inc Gene associe au diabete sucre du type 2 et son utilisation

Also Published As

Publication number Publication date
WO2006063703A8 (fr) 2007-11-08
WO2006063703A3 (fr) 2006-10-26
CA2589037A1 (fr) 2006-06-22
EP1828417A2 (fr) 2007-09-05
WO2006063703A2 (fr) 2006-06-22

Similar Documents

Publication Publication Date Title
US20090130660A1 (en) Single Nucelotide Polymorphism (SNP)
US20210095345A1 (en) Method of identifying disease risk factors
EP3068783B1 (fr) Les agonistes de récepteur 2 d'hypocrétine pur l'utilisation dans le traitement d'une insuffisance cardiaque
US20090221670A1 (en) Method for diagnosis and treatment of a mental disease
JP2008523844A5 (ja) ワルファリンの投与範囲を予想する方法
JP2008522597A (ja) Ｉｉ型糖尿病に関連する単一ヌクレオチド多型（ｓｎｐ）
EP1673473A1 (fr) Utilisation de polymorphismes genetiques compatibles avec l'efficacite de traitement des maladies inflammatoires
Dias et al. Genetic variations at the human growth hormone receptor (GHR) gene locus are associated with idiopathic short stature
AU2009246086B2 (en) Asthma susceptibility loci located at chromosome 1q31 for use in diagnostic and therapeutic methods
US20220349008A1 (en) Novel genetic markers for postural orthostatic tachycardia syndrome (pots) and methods of use thereof for diagnosis and treatment of the same
JP5904501B2 (ja) ２型糖尿病の検出方法
AU2004283234B2 (en) Use of genetic polymorphisms to predict drug-induced hepatotoxicity
EP1100962A1 (fr) Polymorphismes genetiques du gene du recepteur neurokininique 1 de l'homme et leurs utilisations pour le diagnostic et le traitement d'affections
JP4317376B2 (ja) 糖尿病性腎症遺伝子の検出方法
US20020160362A1 (en) Diagnostic method
JP5422805B2 (ja) 新規糖尿病性腎症感受性遺伝子
AU2013202634B2 (en) Method of identifying disease risk factors
WO2006073183A1 (fr) Procede d'evaluation d'une maladie inflammatoire au moyen d'un polymorphisme de nucleotide simple
US20060166217A1 (en) Genetic marker for coronary artery disease
CN101133165A (zh) 与ⅱ型糖尿病相关的单核苷酸多态性（snp）
WO2010022235A2 (fr) Une étude d'association à l'échelle du génome sur l'autisme révèle un nouveau locus à risque commun sur 5p14.1
WO2000034515A1 (fr) Utilisation du polymorphisme du facteur x dans le diagnostic et le traitement d'affections induites par le facteur x et/ou xa

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100415

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20101027